Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
32 Leser
Artikel bewerten:
(0)

India IVD Market Report 2016 - Total Sales 2015-2025

DUBLIN, Feb. 22, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/2ggndk/ivd_in_india) has announced the addition of the "IVD in India" report to their offering.

India as an IVD market opportunity is defined by its standing next to other populous countries with demonstrated economic promise for over the past decade - Brazil, Russia and China. IVD in India places India and its in vitro diagnostics (IVD) market in context, presenting current analysis of the Indian IVD industry and providing forecasts to 2025.

The report takes an in-depth look at the market, providing data on the size and growth of the total Indian market as well as on the following IVD in India market segments:

  • Immunoassays
  • Clinical Chemistry
  • Hematology
  • Point of Care/OTC
  • Molecular
  • Urinalysis
  • Other IVD Tests

The report features a ten year forecast period, with projections of the total Indian IVD market and its component segments from 2015-2025, including:

  • Total IVD Sales in India, 2015-2025
  • IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2015
  • IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2020
  • IVD Sales in India by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2025

IVD in India presents the main issues and trends affecting this market, influencing its move into the future.

Some of these include:

  • The Future of Indian Economic Growth
  • Market Segment Opportunities
  • BRIC Metrics - Indian IVD Market in Context
  • IVD Spending
  • Strengths - Conditions That Support Market Growth
  • Weaknesses - Factors That Pose Barriers to Market Success and Entry
  • Opportunities - Rural Healthcare and Technology Partnerships
  • Threats - Domestic and Chinese Competition

Key Topics Covered:

One: Executive Summary

Two: Introduction to Health Care and Diagnostics in the Developing World - India in Context

Three: India IVD SWOT Analysis

Four: India IVD Market Size

Five: Industry and Company Activity in India

Companies Featured

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Alere
  • Arkray
  • Beckman Coulter, Inc./Danaher
  • Becton, Dickinson & Co
  • Biohit Oy
  • bioMérieux, Inc.
  • Bio-RAD Laboratories, Inc.
  • Daan Gene Co., Ltd.
  • Danaher Corp.
  • Gen-Probe, Inc.
  • Grifols
  • Hologic, Inc.
  • Horiba Medical
  • Instrumentation Laboratory
  • Laboratory Corporation of America
  • Luminex Corporation
  • MedMira
  • Mindray Medical International, Ltd.
  • Myriad Genetics
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Promega Corporation
  • QIAGEN N.V.
  • Quest Diagnostics
  • Radiometer A/S
  • Roche
  • Shanghai Fosun Pharmaceutical Co. Ltd.
  • Shanghai Kehua Bio-engineering
  • Siemens
  • SRL Diagnostics
  • Sysmex Corp.
  • Thermo Fisher Scientific

For more information visit http://www.researchandmarkets.com/research/2ggndk/ivd_in_india

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.